Targeting HER2: recent developments and future directions for breast cancer patients
W Shao-Chun, Z Lisha, GN Hortobagyi… - Seminars in oncology, 2001 - Elsevier
Overexpression of the HER2/neu oncogene (also known as c-erbB2) is a frequent molecular
event in multiple human cancers, including breast and ovarian cancer. Patients with cancer
that overexpress HER2/neu are associated with unfavorable prognosis, shorter relapse time,
and low survival rate. Treatments that target HER2/neu expression in cancer cells have
been shown to be useful strategies to significantly reverse the malignancy induced by
HER2/neu overexpression. The humanized anti-HER2/neu antibody, trastuzumab …
event in multiple human cancers, including breast and ovarian cancer. Patients with cancer
that overexpress HER2/neu are associated with unfavorable prognosis, shorter relapse time,
and low survival rate. Treatments that target HER2/neu expression in cancer cells have
been shown to be useful strategies to significantly reverse the malignancy induced by
HER2/neu overexpression. The humanized anti-HER2/neu antibody, trastuzumab …
